These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15449188)

  • 1. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
    Terpos E; Politou M; Rahemtulla A
    J Cancer Res Clin Oncol; 2004 Oct; 130(10):623-5. PubMed ID: 15449188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
    Jaskiewicz AD; Herrington JD; Wong L
    Pharmacotherapy; 2005 Dec; 25(12):1820-5. PubMed ID: 16305302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
    Suzuki K; Terui Y; Nishimura N; Ueda K; Mishima Y; Sakajiri S; Yokoyama M; Aiba K; Hatake K
    Jpn J Clin Oncol; 2014 May; 44(5):435-41. PubMed ID: 24664944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
    Nakamura S; Yata K; Jinno T; Harada T; Fujii S; Miki H; Nakano A; Kagawa K; Takeuchi K; Ozaki S; Abe M; Matsumoto T
    Rinsho Ketsueki; 2010 Aug; 51(8):690-5. PubMed ID: 20805677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
    Arai A; Oshikawa G; Kurosu T; Miki T; Tohda S; Koyama T; Murakami N; Miura O
    Rinsho Ketsueki; 2006 Aug; 47(8):777-80. PubMed ID: 16986718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment.
    Wang L; Jian Y; Yang G; Gao W; Wu Y; Zuo L
    Clin J Oncol Nurs; 2015 Feb; 19(1):E4-7. PubMed ID: 25689664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib-associated tumor lysis syndrome in multiple myeloma.
    Furtado M; Rule S
    Leuk Lymphoma; 2008 Dec; 49(12):2380-2. PubMed ID: 19052991
    [No Abstract]   [Full Text] [Related]  

  • 8. Bortezomib-induced tumor lysis syndrome in multiple myeloma.
    Sezer O; Vesole DH; Singhal S; Richardson P; Stadtmauer E; Jakob C; Boral AL; Esseltine DL; Mehta J
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):233-5. PubMed ID: 17229340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.
    Kenealy MK; Prince HM; Hönemann D
    Pharmacotherapy; 2006 Aug; 26(8):1205-6; discussion 1206. PubMed ID: 16863501
    [No Abstract]   [Full Text] [Related]  

  • 10. A phase 2 study of bortezomib in relapsed, refractory myeloma.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
    N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
    Richardson P; Jagannath S; Colson K
    Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
    Kondo M; Hotta Y; Yamauchi K; Sanagawa A; Komatsu H; Iida S; Kimura K
    BMC Cancer; 2020 Nov; 20(1):1117. PubMed ID: 33203424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.
    Yamaguchi T; Sasaki M; Itoh K
    Jpn J Clin Oncol; 2012 Jul; 42(7):637-9. PubMed ID: 22628610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-induced rhabdomyolysis in multiple myeloma.
    Cibeira MT; Mercadal S; Arenillas L; Muntañola A; Salamero O; Bladé J
    Acta Haematol; 2006; 116(3):203-6. PubMed ID: 17016040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
    Moon SJ; Min CK; Lee DG; Lee S; Lee JW; Min WS; Kim CC; Kim M; Park G; Kim Y
    Acta Haematol; 2007; 117(4):211-4. PubMed ID: 17237615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
    Lee KW; Yun T; Song EK; Na II; Shin H; Bang SM; Lee JH; Lee ST; Kim JH; Yoon SS; Lee JS; Park S; Kim BK; Kim NK
    J Korean Med Sci; 2005 Aug; 20(4):598-62. PubMed ID: 16100450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-induced Sweet's syndrome confirmed by rechallenge.
    Zobniw CM; Saad SA; Kostoff D; Barthel BG
    Pharmacotherapy; 2014; 34(4):e18-21. PubMed ID: 24338786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma.
    Lipstein M; O'Connor O; Montanari F; Paoluzzi L; Bongero D; Bhagat G
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):E43-6. PubMed ID: 21856550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.